By Jacob Gronholt-Pedersen (Reuters) -Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later ...

Shares of Novo Nordisk (NYSE: NVO) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

Novo Nordisk is a healthcare stock that is down 50% in 2025. Is NVO stock undervalued at current levels or can it move lower ...

Both Novo Nordisk's Wegovy and rival Eli Lilly's Zepbound are essentially versions of predecessor diabetes drugs. Some ...

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...

Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under ...

Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

President Donald Trump's new European tariffs could significantly increase the cost of Novo Nordisk's weight loss drug, Ozempic.

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

Eli Lilly (NYSE:LLY) stock rose 1.3% and Novo Nordisk (NYSE:NVO) shares jumped 2% Friday morning after The Washington Post ...